Bonita David P 4

What Happened
Bonita David P, listed as a 10% owner, acquired a total of 2,815,315 shares of Prelude Therapeutics (PRLD) on April 21, 2026. The purchases were two lots of 1,689,189 shares and 1,126,126 shares, each priced at $4.44 per share, for aggregate proceeds of $7,499,999 and $4,999,999 respectively (total ≈ $12,499,998). These were purchases (P) — a direct buy rather than a sale.

Key Details

• Transaction date: 2026-04-21; Filing date (Form 4): 2026-04-23 (filed within the typical two-business-day window).
• Price per share: $4.44 for both lots.
• Shares purchased: 1,689,189 and 1,126,126 (total 2,815,315).
• Total disclosed purchase value: approximately $12.5 million.
• Footnote F1: Securities were purchased in an underwritten public offering (not an open-market trade).
• Footnotes F2–F4 & F5: Shares are held of record by OrbiMed funds (e.g., OrbiMed Private Investments VI, OrbiMed Partners Master Fund, OrbiMed Genesis Master Fund). Bonita David P is a member of OrbiMed Advisors; OrbiMed entities may be deemed to have voting/investment power but disclaim beneficial ownership except to the extent of any pecuniary interest.
• Shares owned after the transaction: not specified in the excerpted filing.

Context
This filing reports institutional/management-related purchasing through OrbiMed-affiliated vehicles (a 10% owner), not an individual executive's open-market trade. Purchases in an underwritten offering can reflect participation by existing investors or allocated investors rather than opportunistic open-market buying; the filing is factual and does not indicate motive.